Acumen Pharmaceuticals, Inc.
NASDAQ:ABOSBiotechnology
+$0.02 today
- Market cap
- $165.63M
- Beta
- 0.35
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.79
Volume 0.81M
Average 0.40M
ABOS Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Acumen Pharmaceuticals, Inc.NASDAQ: ABOS
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit turns negative
Q1 FY2026 gross profit was -$46K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$46K.
Context
- Gross profit increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly gross profit holds near -$46K or moves back toward the trailing-twelve-month quarterly average of -$11.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | +100.0% |
| FY2021 | 2021-12-31 | (12.31M) | — |
Gross Profit vs competitors
How ABOS compares with its peers on the latest reported figures
- ABOS's LTM Mar 2026 gross profit of -$46K is the 6th highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of -4.5% is the 7th highest of 9, against a peer median of +62.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $64.58M | +289.3% | — | 52.1% | |
| LTM Mar 2026 | $54.77M | +162.7% | +7.1% | 100.0% | |
| LTM Mar 2026 | $7.26M | +61.1% | +70.5% | 48.3% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $5.95M | +1.3% | -29.1% | 49.6% |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | -$46K | -4.5% | — | — | |
| LTM Mar 2026 | -$240K | +97.6% | — | 20.9% | |
| LTM Mar 2026 | -$2.24M | -69.6% | -81.5% | — | |
| LTM Mar 2026 | -$11.28M | -289.4% | -56.0% | 61.2% | |
| LTM Mar 2026 | -$26.26M | +63.7% | — | 415.8% | |
| Peer median (excluding ABOS) | $0 | +62.4% | -29.1% | 52.1% | |
Competitors are the stored peer set for ABOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 12.31M | 0 | 0 | 0 | 0 |
| Gross Profit | (12.31M) | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 12.31M | 32.36M | 42.32M | 93.8M | 104.89M |
| Selling, General & Admin | 7.28M | 12.88M | 18.82M | 20.22M | 18.95M |
| Operating Expenses | 7.28M | 45.24M | 61.14M | 114.02M | 123.83M |
| Depreciation & Amortization | 4K | 169K | 184K | 178K | 184K |
| EBITDA | (100.6M) | (42.69M) | (51.61M) | (98.08M) | (116.93M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (19.58M) | (45.24M) | (61.14M) | (114.02M) | (123.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 84K | 2.39M | 10.79M | 14.32M | 7.45M |
| Interest Expense | 0 | 0 | 581K | 4.07M | 4.22M |
| Other Income / Expenses | (81.02M) | 2.38M | 8.77M | 11.69M | 2.5M |
| Income Before Tax | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.63) | (1.06) | (1.08) | (1.71) | (2.00) |
| EPS (Diluted) | (2.63) | (1.06) | (1.08) | (1.71) | (2.00) |
| Weighted Avg Shares | 38.27M | 40.6M | 48.49M | 60.01M | 60.56M |
| Weighted Avg Shares (Diluted) | 38.27M | 40.6M | 48.61M | 60.01M | 60.56M |
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
Intrinsic Alpha fair value
Locked
Current Price
$2.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.